OBJECTIVES The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP).
T he prevalence of acute decompensated heart failure (HF) continues to grow, and the prognosis remains poor despite the availability of many drugs to treat HF (1) . Conventional diuretic agents and vasodilators remain mainstays of therapy (1) , but currently no new drugs have improved the prognosis of patients with acute decompensated HF (2) (3) (4) (5) . In addition, myocardial remodeling is driven by decreased cyclic guanosine monophosphate (cGMP) activity in cardiac myocytes in both HF with preserved ejection fraction (EF) and advanced HF with reduced EF (6) , suggesting that cGMP replacement therapy may be useful in patients with HF.
The cardiac guanylyl cyclase receptor-A (GC-A)
activators atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) play roles in circulating volume and blood pressure homeostasis (7, 8) The molecular precursor of ANP, proANP, is formed after removal of the signal peptide from pre-proANP, which is produced from the NPPA gene in the heart (11, 12) . ProANP is then processed into amino-terminal proANP and the biologically active ANP by corin (13, 14) (Online Figure 1) . ProANP is stored in secretory granules in atrial cardiomyocytes and cleaved to ANP upon secretion, in response to stretch (15) . ANP is then degraded into smaller molecular fragments by neprilysin and insulin-degrading enzyme (16) (17) (18) . Hunter et al. (19) reported that proANP circulates in canines and humans.
Although initially circulating pro-natriuretic peptides were not thought to be biologically active, we and others have recently established proBNP is active, has a longer half-life than BNP in rats (20) , and can be processed to BNP in human serum (21) , but it is unclear if this is true for proANP.
As with proBNP (20), we hypothesized that proANP would be biologically active in vivo, with a longer half-life and longer lasting cardiorenal actions than ANP or BNP. Furthermore, we hypothesized that proANP can stimulate cGMP production via GC-A receptors and be processed to ANP in the circulation. These studies advance our understanding of proANP, ANP, GC-A, and cGMP signaling in the circulation, with potential physiological and therapeutic implications. Inulin was continuously infused for measurement of glomerular filtration rate, which was calculated by inulin clearance. Plasma and urinary sodium, potassium, and lithium levels were determined. Urinary excretion of each parameter (X), such as cGMP, sodium, or potassium, was determined as X Â urine volume (UV) (milliliters per minute). Using the lithium clearance technique, we calculated renal tubular function, proximal fractional reabsorption of sodium (PFR Na ), and distal fractional reabsorption of sodium (DFR Na ) (23, 24) . Levels of cGMP were assayed using the RIA cGMP kit (Perkin-Elmer, Waltham, Massachusetts) (22) (23) (24) . Pharmacokinetic profiles were calculated by noncompartmental analysis using Phoenix WinNonline 6.3 software (Certara, Princeton, New Jersey) (26) .
METHODS

All
IN VITRO STUDY IN HUMAN EMBRYONIC KIDNEY 293 CELLS
Human embryonic kidney 293 (HEK293) cells were stably transfected with either human GC-A or guanylyl cyclase receptor-B (GC-B) using Lipofectamine (Invitrogen, Grand Island, New York) (27) . Cells were treated with or without 10 À10 to 10 À8 mol/l proANP, ANP, BNP, or CNP for 10 min, and intracellular cGMP levels were measured.
EX VIVO HUMAN STUDIES. Fresh serum was obtained from healthy volunteers (normal control subjects) and patients with HF (New York Heart Association functional class II to IV), with informed consent.
Fresh serum (100 ml) with or without 500 ng Trx-and His-tagged proANP (1.9 Â 10 À7 mol/l) added was incubated for varying times from 5 to 180 min at 37 C, then immunoprecipitated and Western-blotted using
His-tag antibody (21, 28) . Ichiki et al.
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ProANP Bioavailability Compared With ANP or BNP when the global test was significant. Two-way analysis of variance was used to compare between groups in time-course in vivo studies, followed by Bonferroni post-tests. GraphPad Prism 5 (GraphPad Software, La Jolla, California) and JMP 10 (SAS Institute, Cary, North Carolina) were used for these calculations. Statistical significance was accepted at p < 0.05.
RESULTS
IN VIVO RENAL ACTIONS. Online Table 1 illustrates baseline characteristics in each group. There was no statistical difference among the groups. We calculated the value of the difference from baseline (0 min) before drug injection for each parameter to compare among the groups.
ProANP resulted in biphasic increases in UV and urinary sodium excretion with the first peak at 10 min and the second peak between 60 and 90 min, whereas ANP and BNP showed a monophasic increase peak at 10 min ( Figures 1A and 1B) . ANP also had a lower peak than proANP and BNP. Urinary potassium excretion followed the same pattern with proANP, whereas ANP and BNP decreased sharply in the first 45 min, with BNP remaining low while ANP slowly increased over the next 150 min (Online Table 2 ). ProANP had significantly greater total UV for 3 h, but neither ANP nor BNP significantly changed from placebo ( Figure 1C ). ProANP and BNP had significantly greater total sodium excretion than placebo, but ANP did not ( Figure 1D ). All 3 peptides had no significant differences compared with placebo in total potassium excretion (data not shown).
ProANP significantly increased renal blood flow from 45 to 150 min compared with ANP and BNP (Figure 2A) , and proANP had a greater increase in glomerular filtration rate at 10 min compared with ANP or BNP (Online Table 2 ). ProANP showed the greatest increase in hematocrit from 30 to 180 min, possibly because of Ichiki et al.
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volume loss caused by diuresis ( Figure 2B ). To determine which nephron segment was involved in the greater natriuretic response to proANP, we analyzed PFR Na and DFR Na , as shown in Online Table 2 . ProANP significantly decreased PFR Na at 10 min, similar to ANP and BNP but showed a biphasic effect like UV ( Figure 1A) and urinary sodium excretion ( Figure 1B) , with a significantly prolonged decrease of PFR Na over 120 min compared with the other 3 groups. ProANP also significantly decreased DFR Na , with a peak at 10 min, and showed a significantly prolonged decrease of DFR Na for 60 min compared with its baseline as well as placebo.
ANP and BNP lacked the prolonged effects.
IN VIVO HEMODYNAMIC ACTIONS. Figure 3 and Online Table 2 We assessed whether proANP is processed in the normal or HF human circulation ex vivo. Characteristics of normal control subjects and patients with HF and individual characteristics of patients with HF are shown in Online Tables 3 and 4. All patients were in the hospital and had moderate to severe HF.
As shown in Figure 5A , proANP was produced with an N-terminal Trx-tag to aid in peptide purification and a C-terminal His-tag to aid in the isolation of ANP forms after processing. His-tag antibodies will detect unprocessed proANP, proANP without the 
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Trx-tag, and ANP but not processed aminoterminal proANP ( Figure 5A ). ProANP (w23 kDa) was processed into a smaller molecular weight form (w4 kDa) ( Figures 5B and 5C ) in serum from normal control subjects and patients with HF, which was confirmed to be ANP by sequencing. In some subjects, a faint band around 13 kDa was determined to be proANP without the Trx-tag ( Figure 5B ). To date, the in vivo physiological actions of proANP have not been defined, although de Bold (29) previously reported that extracts from the atrial myocardium, which contained atrial natriuretic factor, but most likely proANP as well, had potent diuretic, natriuretic, and blood pressure-lowering properties. In our study, we observed that proANP had greater and more prolonged cGMP activation than ANP, while the area under the curve of BNP for both plasma cGMP and urinary cGMP excretion (Online Figure 2) was the highest of all 3 peptides.
Unexpectedly, proANP had significantly greater natriuretic and diuretic actions than ANP or BNP ( Figures 1A and 1B) . These greater renal actions were a result of greater tubular actions and greater increases in renal blood flow and glomerular filtration rate. The cardiorenal differences between proANP and mature ANP may be due to: 1) the longer half-life of proANP;
2) "dual" activating properties of proANP via proANP and "processed to ANP" forms; and/or 3) conversion of proANP to active ANP forms; such as vessel dilator (ANP ), which works in the kidney through a noncGMP pathway (30) . Indeed, we speculate that the vessel dilator form may explain the second peak of proANP urinary actions, which seems to occur via noncGMP activation, as urinary cGMP was not biphasic.
Beyond the kidney, we report that proANP reduced cardiac filling pressures, including reductions in pulmonary artery pressure, PCWP, right atrial pressure, and systemic vascular resistance, with increases in HR and hematocrit compared with baseline. In contrast, these hemodynamic effects were not observed with ANP. Notably, proANP markedly increased HR over 120 min ( Figure 3D) . We speculate that the increased HR might be in response to volume loss associated with decreased hematocrit ( Figure 2B Although our studies support proANP as a direct activator of GC-A, in fact a dual mechanism for GC-A activation may be at play, as we demonstrate that proANP can be processed to biologically active ANP in
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ProANP Bioavailability Compared With ANP or BNP human serum, similar to our previous studies on proBNP processing in the circulation (21) . It has been reported that corin is present in the circulation and kidneys (32) , supporting potential proANP cleavage to ANP in these locations (13, 14) . Similar to normal human serum, proANP was rapidly processed to ANP in patients with HF. Thus, our human proANP could activate GC-A either directly or indirectly through processing to ANP in either normal control subjects or patients with HF. These results are in contrast to those from our studies of proBNP processing and degradation, in which the cGMP activity of proBNP was much less than BNP, proBNP processing to BNP was rapid with degradation complete within 60 min in normal control subjects, and proBNP processing was delayed (28) . These differences in metabolism and bioactivity between proANP and proBNP may be key factors in cardiovascular homeostasis. TRANSLATIONAL OUTLOOK: Our studies advance our understanding of the heart as an endocrine organ and the proANP, ANP, GC-A, and cGMP system with biological, diagnostic, and therapeutic implications.
Because proANP circulates, we must now consider it as a biologically active hormone, and it may be useful to develop assays that explore its biomarker potential.
Finally, its unique renal and cardiac unloading actions may also lay the foundation for its development as a new therapy for cardiorenal disease. Ichiki et al. 
